Sclerotherapy of Ovarian Endometriomas During Oocyte Preservation: A Prospective Feasibility Cohort Study

Tudela CL, César Lizán Tudela, Laura Gregori Navarro, Navarro LG, García AV, Alba Verdú García, Raúl Gómez Gallego, Gallego RG, Lorenzo Abad de Velasco, de Velasco LA, Baixauli FR, Francisco Raga Baixauli
Journal of minimally invasive gynecology · 2026 · doi:10.1016/j.jmig.2026.06.020 · PMID:42476497 · W7169767970
article OA: closed public-domain-us
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-22 ⓘ

Concurrent transvaginal oocyte retrieval and ethanol sclerotherapy of ovarian endometriomas significantly reduced cyst volume and improved pain and quality of life with one serious complication.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the feasibility, safety, and preliminary efficacy of concurrent transvaginal ovarian puncture for oocyte retrieval and ethanol sclerotherapy of ovarian endometriomas (eSCLT) during controlled ovarian stimulation. DESIGN: Prospective single-center pilot cohort study with a before-after design and no randomization. SETTING: Assisted Reproductive Technology Unit of a public tertiary hospital in Spain. PATIENTS: Twenty-three women aged 18-40 years seeking fertility preservation, presenting with unilateral endometrioma ≥3 cm or bilateral endometrioma with at least one cyst >3 cm. INTERVENTIONS: Combined transvaginal oocyte pick-up followed by ultrasound-guided eSCLT. MEASUREMENTS AND MAIN RESULTS: Endometrioma volume reduction and symptomatic improvement assessed by Visual Analog Scale (VAS) pain scores and Endometriosis Health Profile-30 (EHP-30). Secondary outcomes included variations in ovarian reserve parameters (antral follicle count [AFC] and anti-Müllerian hormone [AMH]) assessed before the procedure and at 3-month follow-up). Endometrioma volume showed a statistically significant reduction from a mean (SD) of 53.04 (39.34) cm3 pre-intervention to 8.32 (9.20) cm3 at 3 months (p=0.002). VAS scores decreased from 7.24 (1.82) to 5.53 (2.63) (p=0.037), and EHP-30 total scores improved from 78.35 (17.92) to 48.53 (18.95) (p<0.001). Ovarian reserve markers remained stable (AMH: 2.50 [2.03] vs 2.37 [1.94] ng/mL, p=0.82; AFC increased from 9.50 [6.16] to 14.10 [8.33] follicles, p=0.03). One Clavien-Dindo Grade III complication (infection requiring surgical intervention) occurred. CONCLUSION: This pilot study suggests that combined oocyte vitrification and eSCLT is a feasible minimally invasive approach associated with substantial cyst volume reduction and improvements in pain and quality of life. These findings should be interpreted as preliminary and hypothesis-generating, warranting validation in controlled comparative studies.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

SciLite annotations

chemicals 1
ethanol

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-07-26T06:00:49.253533+00:00
pubmed
last seen: 2026-07-26T06:02:57.353089+00:00
scilite
last seen: 2026-07-26T09:53:43.985191+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine